Ovna has an exclusive license for three technologies developed at UT-Austin and MD Anderson. These technologies involve proprietary cancer detection and monitoring solutions. Targets are oral cancer, skin cancer, and then cancer margin detection. Additional revenue will come through disposable equipment covers, as well as through sub-licensing in select categories. A 27 patient trial has been completed and a 150 patient trial started in December.